SCHEMBL1287276

SCHEMBL1287276

O=c1cc(Cc2ccccc2)[nH]c(=O)[nH]1

nearest known ligand 0.69

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.69
YTHDC1 Q96MU7 1/20 0.55
GPR84 Q9NQS5 3/20 0.50
RAB9A P51151 1/20 0.49
DAO P14920 1/20 0.49
TYMP P19971 3/20 0.47
PARP1 P09874 1/20 0.47
TP53 P04637 1/20 0.47
HSD17B10 Q99714 1/20 0.47
ALDH1A1 P00352 1/20 0.46
HCAR2 Q8TDS4 1/20 0.45
UNG P13051 1/20 0.45
ADORA1 P30542 1/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dimethylamine SCHEMBL27691701 0.95 SMN1; SMN2 (0.63) SMN1; SMN2YTHDC1GPR84RAB9ADAO
SCHEMBL14426642 0.82 RAB9A (0.72) SMN1; SMN2YTHDC1GPR84RAB9ATYMP
Benzylthiouracil SCHEMBL815137 0.81 SMN1; SMN2 (1.00) SMN1; SMN2GPR84DAOPARP1ALDH1A1
SCHEMBL14123282 0.80 HRH4 (0.51) SMN1; SMN2YTHDC1RAB9ADAOALDH1A1
SCHEMBL14917577 0.79 SMN1; SMN2 (0.62) SMN1; SMN2GPR84DAOPARP1HSD17B10
SCHEMBL20599951 0.79 TSHR (0.50) SMN1; SMN2YTHDC1GPR84RAB9ADAO
SCHEMBL17206126 0.78 GPR84 (0.73) SMN1; SMN2GPR84
Diphenylmethane SCHEMBL10711103 0.77 CALM1 (0.63) SMN1; SMN2DAOTYMPPARP1HSD17B10
SCHEMBL6613866 0.75 SMN1; SMN2 (0.57) SMN1; SMN2GPR84DAOPARP1HCAR2
SCHEMBL13757285 0.74 DAO (0.49) SMN1; SMN2DAOTYMPALDH1A1HCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1001789-B1 PRODUCT COMPRISING AT LEAST A DOUBLE STRANDED RNA COMBINED WITH AT LEAST A 6-BENZYLURACIL DERIVATIVE FOR A SIMULATNEAOUS, SEPARATED OR TIME-SPREADED THERAPEUTIC USE SOD CONSEILS RECH APPLIC (FR) 2002-11-06 EP claimed
EP-1001789-A1 PRODUCT COMPRISING AT LEAST A DOUBLE STRANDED RNA COMBINED WITH AT LEAST A 6-BENZYLURACIL DERIVATIVE SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2000-05-24 EP claimed
WO-1999007384-A1 PRODUCT COMPRISING AT LEAST A DOUBLE STRANDED RNA COMBINED WITH AT LEAST A 6-BENZYLURACIL DERIVATIVE SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 1999-02-18 WO claimed
WO-2024137865-A1 COMPOUNDS USEFUL AS T CELL ACTIVATORS GOSSAMER BIO SERVICES, INC. (US) 2024-06-27 WO disclosed
EP-4262986-A1 COMPOUNDS USEFUL AS T CELL ACTIVATORS Gossamer Bio Services, Inc. (US) 2023-10-25 EP disclosed
US-20230271954-A1 COMPOUNDS USEFUL AS T CELL ACTIVATORS GOSSAMER BIO SERVICES INC (US) 2023-08-31 US disclosed
WO-2023122772-A1 OXIME DERIVATIVES USEFUL AS T CELL ACTIVATORS GOSSAMER BIO SERVICES, INC. (US) 2023-06-29 WO disclosed
WO-2023122778-A1 PYRIDAZINONE DERIVATIVES USEFUL AS T CELL ACTIVATORS GOSSAMER BIO SERVICES, INC. (US) 2023-06-29 WO disclosed
WO-2023122777-A1 OXIME DERIVATIVES USEFUL AS T CELL ACTIVATORS GOSSAMER BIO SERVICES, INC. (US) 2023-06-29 WO disclosed
WO-2022133083-A1 COMPOUNDS USEFUL AS T CELL ACTIVATORS GOSSAMER BIO SERVICES, INC. (US) 2022-06-23 WO disclosed
CN-102838549-A New class of 1,5,6-substituted pyrimidine derivatives with anti-HIV virus effects UNIV BEIJING 2012-12-26 CN disclosed
WO-2006070292-A2 PYRIMIDINE COMPOUNDS AS ANTI-ICTOGENIC AND/OR ANTI-EPILEPTOGENIC AGENTS QUEEN'S UNIVERSITY AT KINGSTON (US) 2006-07-06 WO disclosed
US-20040171652-A1 Antiviral and spermicidal contraceptives; 2-thiourea pyridinyl derivative containing compositions PARKER HUGHES INSTITUTE 2004-09-02 US disclosed
US-6774139-B1 CONTRACEPTIVES PARKER HUGHES INSTITUTE 2004-08-10 US disclosed
EP-1001789-B1 PRODUCT COMPRISING AT LEAST A DOUBLE STRANDED RNA COMBINED WITH AT LEAST A 6-BENZYLURACIL DERIVATIVE FOR A SIMULATNEAOUS, SEPARATED OR TIME-SPREADED THERAPEUTIC USE SOD CONSEILS RECH APPLIC (FR) 2002-11-06 EP disclosed
EP-1001789-B1 PRODUCT COMPRISING AT LEAST A DOUBLE STRANDED RNA COMBINED WITH AT LEAST A 6-BENZYLURACIL DERIVATIVE FOR A SIMULATNEAOUS, SEPARATED OR TIME-SPREADED THERAPEUTIC USE SOD CONSEILS RECH APPLIC (FR) 2002-11-06 EP disclosed
EP-1001789-A1 PRODUCT COMPRISING AT LEAST A DOUBLE STRANDED RNA COMBINED WITH AT LEAST A 6-BENZYLURACIL DERIVATIVE SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2000-05-24 EP disclosed
EP-1001789-A1 PRODUCT COMPRISING AT LEAST A DOUBLE STRANDED RNA COMBINED WITH AT LEAST A 6-BENZYLURACIL DERIVATIVE SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2000-05-24 EP disclosed
WO-1999007384-A1 PRODUCT COMPRISING AT LEAST A DOUBLE STRANDED RNA COMBINED WITH AT LEAST A 6-BENZYLURACIL DERIVATIVE SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 1999-02-18 WO disclosed
WO-1999007384-A1 PRODUCT COMPRISING AT LEAST A DOUBLE STRANDED RNA COMBINED WITH AT LEAST A 6-BENZYLURACIL DERIVATIVE SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 1999-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271954-A1 COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKZ, DGKA, DGKG SMN1; SMN2 4536/4885YTHDC1 3374/4885GPR84 938/4885
US-20040171652-A1 Antiviral and spermicidal contraceptives; 2-thiourea pyridinyl derivative containing compositions ZP1, NASP, SAMHD1 SMN1; SMN2 2941/4885YTHDC1 518/4885GPR84 4441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.